We will be contrasting the differences between INSYS Therapeutics Inc. (NASDAQ:INSY) and ContraFect Corporation (NASDAQ:CFRX) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSYS Therapeutics Inc.	82.08M	4.38	124.51M	-1.60	0.00
ContraFect Corporation	N/A	0.00	37.68M	-0.65	0.00

In table 1 we can see INSYS Therapeutics Inc. and ContraFect Corporation’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both businesses.

	Net Margins	Return on Equity	Return on Assets
INSYS Therapeutics Inc.	-151.69%	-362%	-50.8%
ContraFect Corporation	0.00%	-539.9%	-113%

Risk & Volatility

INSYS Therapeutics Inc. has a beta of 2.56 and its 156.00% more volatile than S&P 500. ContraFect Corporation on the other hand, has -0.49 beta which makes it 149.00% less volatile compared to S&P 500.

Liquidity

INSYS Therapeutics Inc. has a Current Ratio of 0.7 and a Quick Ratio of 0.6. Competitively, ContraFect Corporation’s Current Ratio is 7.2 and has 7.2 Quick Ratio. ContraFect Corporation’s better ability to pay short and long-term obligations than INSYS Therapeutics Inc.

Analyst Recommendations

INSYS Therapeutics Inc. and ContraFect Corporation Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
INSYS Therapeutics Inc.	1	0	3	2.75
ContraFect Corporation	0	0	0	0.00

The average price target of INSYS Therapeutics Inc. is $7.75, with potential upside of 60.46%.

Insider & Institutional Ownership

The shares of both INSYS Therapeutics Inc. and ContraFect Corporation are owned by institutional investors at 18.9% and 55.8% respectively. Insiders owned 63.83% of INSYS Therapeutics Inc. shares. Competitively, 10% are ContraFect Corporation’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
INSYS Therapeutics Inc.	0.95%	83.82%	2.42%	-20.1%	-13%	81.71%
ContraFect Corporation	-0.11%	-7.88%	-78.43%	-77.25%	-72.81%	-69.97%

For the past year INSYS Therapeutics Inc. had bullish trend while ContraFect Corporation had bearish trend.

Summary

INSYS Therapeutics Inc. beats ContraFect Corporation on 6 of the 10 factors.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.